J&J-Bayer’s Xarelto Wins U.S. Approval for Hip Surgery Use
This article is for subscribers only.
Johnson & Johnson and Bayer AG’s Xarelto pill won U.S. approval for orthopedic-surgery patients today, expanding the blood thinner’s presence in a market to block clots expected to reach as much as $15 billion annually.
The Food and Drug Administration cleared Xarelto as an alternative for preventing blood clots in patients after hip or knee surgery, the companies said today in a statement.